ESR1 and breast carcinoma: No statistically significant differences in associations with CBC risk were observed for tamoxifen use by age at first breast cancer or year at first breast cancer, family history of breast cancer, BMI or ER/PR status of first breast cancer (P heterogeneity = 0.1–0.9) (Table 4).